FDA has issued fewer guidance documents and delayed some key rules during Scott Gottlieb's first 100 days as agency chief, but has yet to chop any major existing regulations despite the strong deregulatory press by a Trump White House intent on scaling back federal regulations. Industry stakeholders and some congressional Republicans are satisfied with Gottlieb's approach to date, but consumer advocates are still wary of the slowed regulatory pace. The advocates hold up FDA's delay of a highly watched tobacco...